Epithalon

Epithalon, also known as Epitalon or Epithalone, is a tetrapeptide, Ala-Glu-Asp-Gly (AEDG), synthesized based on the amino acid composition of Epithalamin, a bovine pineal gland extract. ^[1] Over the last 25 years it has been extensively studied using in vitro, in vivo, and in silico methods, with results indicating geroprotective and neuroendocrine effects. ^[1] It is classed among investigational, non-approved therapeutic peptides that show promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation. ^[2]

Epithalon has been reported to exert a direct influence on melatonin synthesis, alter the mRNA levels of interleukin-2, modulate the mitogenic activity of murine thymocytes, and enhance the activity of various enzymes including telomerase, though it remains uncertain whether these are its sole mechanisms of action. ^[1] At the cellular level the AEDG peptide is described as regulating the expression of circadian-rhythm genes, reducing the synthesis of apoptosis-promoting proteins such as p16, p21 and p53, and regulating markers of functional cell activity including SIRT1 and SIRT6. ^[3] In animal studies Epitalon restored melatonin secretion in the pineal gland and had strong regulatory activity on the neuroimmunoendocrine and antioxidant systems of the organism. ^[4]

In animal models Epitalon has been reported to increase the lifespan of mice and fruit flies and to restore the circadian rhythms of melatonin and cortisol production in old rhesus monkeys. ^[5] In geroprotection studies, the synthetic peptide bioregulator Epitalon was among substances that inhibited age-related alterations and spontaneous tumour development and showed life span extension in several mouse strains, with effects depending on dose, administration conditions, and genetic predisposition. ^[6] A 2026 gerontology review that identified epitalon under telomere biology concluded that non-approved investigational peptides showed promising preclinical and limited clinical evidence but require rigorous validation through well-designed clinical trials to establish safety and efficacy for healthspan extension. ^[2] Although preclinical studies of recovery-enhancing peptides such as epithalon are promising, there is a current lack of clinical trials. ^[7]

Much of the evidence base for Epitalon derives from experimental and animal models, and it remains uncertain whether its reported mechanisms are the sole mechanisms of action. ^[1] As a non-FDA-approved investigational peptide, it lacks long-term safety data and systematic validation, and significant knowledge gaps include optimal dosing regimens, combination therapy effects, and biomarkers for monitoring efficacy. ^[2]